Actionable news
0
All posts from Actionable news
Actionable news in IONS: IONIS PHARMACEUTICALS Inc COMMON STOCK,

New Data Presented at Peripheral Nerve Society Meeting Further Support Potential Benefit of Inotersen

Significant benefit observed for both clinical measurements of neurological disease progression and quality of life at 8 and 15 months in patients with FAP

CARLSBAD, Calif., July 10, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) presented new top-line data from the Phase 3 NEURO-TTR study of inotersen in patients with familial amyloid polyneuropathy (FAP) at the 2017 Peripheral Nerve Society Meeting. Results from the study demonstrated benefit across both primary endpoints of the study: modified Neuropathy Impairment Score +7 (mNIS+7) and Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) at 15 months of treatment. Inotersen-treated patients benefited significantly in quality of life compared to placebo, with a difference in magnitude of 11.68 points in the Norfolk QoL-DN score at 15 months of treatment (mean change from baseline of 0.99 vs. 12.67, p=0.0006). Statistically significant benefit was also observed for both mNIS+7 and Norfolk QoL-DN at eight months of treatment with inotersen. The results continue to support the...


More